Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIMNASDAQ:CELZNASDAQ:IMACNASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$8.85-3.5%$9.11$0.06▼$14.93$6.76M0.94564,209 shs3,647 shsCELZCreative Medical Technology$2.68+0.4%$2.23$1.69▼$6.90$6.90M2.0456,729 shs12,219 shsIMACIMAC$0.05$0.04$0.75▼$1.65$1.32M-0.88708,132 shs1,892 shsSBFMSunshine Biopharma$1.54-7.0%$1.45$1.17▼$7.60$7.06M1.44601,021 shs292,844 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%-0.78%-3.17%-3.17%-76.94%CELZCreative Medical Technology0.00%+1.13%+18.06%+16.02%-29.84%IMACIMAC0.00%-0.20%+25.00%-15.11%-96.95%SBFMSunshine Biopharma0.00%+4.78%+1.66%-2.23%+383.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech2.0324 of 5 stars3.50.00.00.02.41.70.0CELZCreative Medical Technology0.9745 of 5 stars0.03.00.00.02.70.01.3IMACIMACN/AN/AN/AN/AN/AN/AN/AN/ASBFMSunshine Biopharma2.6544 of 5 stars3.55.00.00.00.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.003,007.34% UpsideCELZCreative Medical Technology 0.00N/AN/AN/AIMACIMAC 0.00N/AN/AN/ASBFMSunshine Biopharma 3.00Buy$15.00877.20% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K46.31N/AN/A$0.20 per share44.25CELZCreative Medical Technology$10K694.12N/AN/A$3.63 per share0.74IMACIMAC$15.22M0.09N/AN/A$0.69 per share0.07SBFMSunshine Biopharma$34.87M0.20N/AN/A$9.10 per share0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/ACELZCreative Medical Technology-$5.49M-$3.81N/AN/AN/AN/A-85.26%-81.49%8/8/2025 (Estimated)IMACIMAC-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/ASBFMSunshine Biopharma-$5.13M-$150.88N/A∞N/A-13.88%-21.25%-16.89%8/15/2025 (Estimated)Latest IMAC, CELZ, AIM, and SBFM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SBFMSunshine BiopharmaN/A-$0.44N/A-$0.44N/A$8.90 million5/9/2025Q1 2025CELZCreative Medical Technology-$0.52-$0.83-$0.31-$0.83N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ACELZCreative Medical TechnologyN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75CELZCreative Medical TechnologyN/A27.4327.42IMACIMAC0.011.271.27SBFMSunshine BiopharmaN/A4.252.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%CELZCreative Medical Technology1.42%IMACIMAC24.27%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%CELZCreative Medical Technology2.80%IMACIMAC10.00%SBFMSunshine Biopharma0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableCELZCreative Medical Technology52.59 million2.51 millionNot OptionableIMACIMAC10626.49 million23.84 millionNot OptionableSBFMSunshine Biopharma34.56 million4.55 millionNot OptionableIMAC, CELZ, AIM, and SBFM HeadlinesRecent News About These CompaniesSunshine Biopharma Launches NIOPEG (R) Into $10 Billion Biologics Market - MorningstarJuly 3 at 7:09 PM | morningstar.comMSBFM - Sunshine Biopharma Inc News - MorningstarJuly 3 at 7:09 PM | morningstar.comMSunshine Biopharma, Inc. (SBFM) - Yahoo FinanceJuly 2 at 11:32 PM | finance.yahoo.comSunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics MarketJuly 2 at 8:00 AM | accessnewswire.comASunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’June 11, 2025 | msn.comSunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion MarketJune 11, 2025 | accessnewswire.comASunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last YearMay 15, 2025 | accessnewswire.comASunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | finanznachrichten.deSunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | accessnewswire.comASunshine Biopharma launches Everolimus in CanadaApril 22, 2025 | markets.businessinsider.comSunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 BillionApril 21, 2025 | accessnewswire.comASunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct OfferingApril 3, 2025 | accessnewswire.comAThis Pharma Stock Is Gaining Major Steam Ahead Of Opening BellApril 2, 2025 | msn.comSunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq RulesApril 2, 2025 | accessnewswire.comASunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer DrugApril 2, 2025 | benzinga.comSunshine Biopharma Announces Positive Results of mRNA Therapy for CancerApril 2, 2025 | finance.yahoo.comSunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last YearApril 1, 2025 | accessnewswire.comASunshine Biopharma signs agreement for rights to market two generic antibioticsMarch 24, 2025 | msn.comSunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in CanadaMarch 24, 2025 | accessnewswire.comASunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonAlphabet Enters a Bull Market: Is It Time to Buy?By Ryan Hasson | June 14, 2025View Alphabet Enters a Bull Market: Is It Time to Buy?Will Warner Bros. Discovery’s Split Produce Double the Upside?By Jeffrey Neal Johnson | June 11, 2025View Will Warner Bros. Discovery’s Split Produce Double the Upside?QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's RallyBy Leo Miller | June 27, 2025View QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's RallyMongoDB Affirms Outlook and Accelerates Stock Price ReversalBy Thomas Hughes | June 6, 2025View MongoDB Affirms Outlook and Accelerates Stock Price ReversalIMAC, CELZ, AIM, and SBFM Company DescriptionsAIM ImmunoTech NYSE:AIM$8.85 -0.32 (-3.49%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$8.95 +0.10 (+1.13%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Creative Medical Technology NASDAQ:CELZ$2.68 +0.01 (+0.37%) As of 07/3/2025 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.IMAC NASDAQ:IMAC$0.05 0.00 (0.00%) As of 07/3/2025IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.Sunshine Biopharma NASDAQ:SBFM$1.54 -0.12 (-6.97%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$1.56 +0.02 (+1.30%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
